Depression today has emerged as a ‘silent killer’ in several regions around the world, particularly in urban cities. The prevalence of depression continues to grow at a rapid pace and has considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit for novel medications and therapies. At present, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants among others. Although these drugs have proved to be highly effective, a large number of patients have reported side effects or have not responded to these drugs in the required manner.
However, advancements in the neurobiology of depression over the past few years have opened up new avenues for antidepressant treatment. In addition, in the current depression drugs market, market participants are increasingly focusing on the development of novel non-pharmacologic and pharmacologic interventions. Research and development activities are expected to continue in full swing during the course of the forecast period. In addition, several drug developers are increasingly pinning their hopes to establish a strong presence in the depression drugs market landscape on the FDA to approve their products.
At the back of these factors, along with growing awareness regarding depression, the global depression drugs market is expected to attain a market value of US$ 24.3 Bn by the end of 2030. The evolving regulatory landscape, along with the fast-paced development of new depression medications are likely to influence the overall growth trajectory of the depression drugs market during the assessment period.
To know the scope of our report Get a Sample on Depression Drugs Market
Major depressive disorder (MDD) continues to remain one of the leading causes of disability around the world. Conventional medications and methods to address depression have repeatedly exhibited a low success rate and are reportedly effective for ~40% patients. These factors have compelled researchers, scientists, and drug developers to explore new pathways that are likely to increase the efficacy of the treatment for major depressive disorder. Research and development activities are likely to influence the overall growth of the depression drugs market. Several research projects around the world are increasingly contributing to the development of novel medications, drugs, and therapies.
For instance, a team of researchers at the Icahn School of Medicine at Mount Sinai, are studying the interleukin-6 molecule– a protein that primarily facilitates communication between different cells. As per the research, individuals suffering from depression have higher levels of IL-6. Another aspect of the research primarily focuses on ezogabine– an anticonvulsant drug that offers immense promise in minimizing symptoms of depression, including low motivation, lack of interest, and inability to feel pressure, among others.
Get a glimpse of the in-depth analysis through our Report Brochure
To date, severe depression is largely treated with tricyclic anti-depressants– a class of drugs that is more effective than other classes of drugs used to address mild to moderate depression. However, the demand for tricyclic anti-depressants is gradually expected to decline due to the side effects associated with them. However, in March 2020, a group of researchers from the University of Copenhagen in collaboration with the National Institutes of Health in Baltimore and Lundbeck A/S has revealed that the team has discovered a potential drug that is likely to ease the side effects of medication that is used to address severe depression.
Conventional classes of drugs, including monoamine oxidase inhibitors and tricyclic antidepressants have remained popular in the depression drugs market over the past three decades. Over time, the uptake of serotonin reuptake inhibitors, first-generation antipsychotics, and various modern forms of psychotherapy has increased at a rapid pace. Although several pharmaceutical companies have gradually refrained from investing resources in research activities due to continual failure of several trials, several market operators have pinned their hopes on ketamine and various other emerging psychiatric medications. The future of the mental health treatment sector primarily depends on two major factors– investments for drug development & clinical trials and approval from the FDA.
The FDA has played an integral role in introducing new drug therapies and medications to the depression drugs market in the U.S. For instance, in March 2019, the FDA approved a unique postpartum depression drugs that has offered promising results in clinical trials. Another major breakthrough in the depression drugs market is the approval of a nasal spray to address treatment-resistant depression. Similar such trends are expected to provide a notable boost to the overall growth of the depression drugs market during the assessment period.
The onset of the novel COVID-19 pandemic is expected to have an impact on the overall growth of the depression drugs market, as a large number of individuals suffering from mental health conditions is increasingly leaning toward prescription drugs such as benzodiazepines and antidepressants. In addition, as governments in several nations have imposed lockdowns as a preventive measure to contain the transmission of the novel coronavirus, the demand for antianxiety medications has witnessed a considerable growth. The number of prescriptions for antidepressants witnessed a noteworthy growth during the first two quarters of 2020 and the trend is likely to continue in the next two quarters of 2020.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
The global depression drugs market is expected to grow at a sluggish CAGR of 2.3% during the forecast period. Much of the market growth can be attributed to ongoing research and development activities, development of novel non-pharmacologic and pharmacologic interventions, increase in the number of collaborations between research institutes and pharmaceutical companies, and most importantly the growing prevalence of mild to severe depression around the world. Market players should focus on improving the effectiveness of their drugs, along with minimizing the side effects of the same.
Depression Drugs Market - Segmentation
TMR’s study on the global depression drugs market includes information divided into four segments: drug class, disease type, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global depression drugs market have been discussed in detail.
| Attribute | Detail |
|---|---|
|
Drug Class |
|
|
Disease Type |
|
|
Distribution Channel |
|
|
Region |
|
The global Depression Drugs Market was worth US$ 18.9 Bn and is projected to reach a value of US$ 24.3 Bn by the end of 2030
Depression Drugs Market is anticipated to grow at a CAGR of 2.3% during the forecast period
North America accounted for a major share of the global Depression Drugs Market
Rise in the number of cases and increase in awareness among patients about diagnosis and treatment of depression are likely to drive the global depression drugs market
Key players in the global Depression Drugs Market include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Allergan, Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott, Pfizer, GlaxoSmithKline
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Depression Drugs Market
4. Market Overview
4.1. Introduction & Overview
4.2. Product Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Depression Drugs Market Analysis and Forecast, 2018-2030
5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Regulatory Scenario
5.4. Key Mergers & Acquisitions
6. Global Depression Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
6.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
6.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
6.2.3. Atypical Antidepressants
6.2.4. Tricyclic Antidepressants
6.2.5. Others
6.3. Global Depression Drugs Market Attractiveness Analysis, by Drug Class
7. Global Depression Drugs Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Global Depression Drugs Market Value (US$) Forecast, by Disease Type, 2018-2030
7.2.1. Major Depressive Disorder
7.2.2. Schizophrenia and Bipolar I Disorder
7.2.3. Obsessive-Compulsive Disorders (OCD)
7.2.4. Anxiety Disorder
7.2.5. Others
7.3. Global Depression Drugs Market Attractiveness Analysis, by Disease Type
8. Global Depression Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Global Depression Drugs Market Attractiveness Analysis, by Distribution Channel
9. Global Depression Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Depression Drugs Market Attractiveness Analysis, by Region
10. North America Depression Drugs Market Analysis and Forecast
10.1. Introduction
10.2. North America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
10.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
10.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
10.2.3. Atypical Antidepressants
10.2.4. Tricyclic Antidepressants
10.2.5. Others
10.3. North America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
10.3.1. Major Depressive Disorder
10.3.2. Schizophrenia and Bipolar I Disorder
10.3.3. Obsessive-Compulsive Disorders (OCD)
10.3.4. Anxiety Disorder
10.3.5. Others
10.4. North America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Depression Drugs Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Disease Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. U.S. Depression Drugs Market Analysis and Forecast
11.1. Introduction
11.2. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
11.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
11.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
11.2.3. Atypical Antidepressants
11.2.4. Tricyclic Antidepressants
11.2.5. Others
11.3. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
11.3.1. Major Depressive Disorder
11.3.2. Schizophrenia and Bipolar I Disorder
11.3.3. Obsessive-Compulsive Disorders (OCD)
11.3.4. Anxiety Disorder
11.3.5. Others
11.4. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. U.S. Depression Drugs Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Disease Type
11.5.3. By Distribution Channel
12. Canada Depression Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
12.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
12.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
12.2.3. Atypical Antidepressants
12.2.4. Tricyclic Antidepressants
12.2.5. Others
12.3. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
12.3.1. Major Depressive Disorder
12.3.2. Schizophrenia and Bipolar I Disorder
12.3.3. Obsessive-Compulsive Disorders (OCD)
12.3.4. Anxiety Disorder
12.3.5. Others
12.4. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Canada Depression Drugs Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Disease Type
12.5.3. By Distribution Channel
13. Europe Depression Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
13.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
13.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
13.2.3. Atypical Antidepressants
13.2.4. Tricyclic Antidepressants
13.2.5. Others
13.3. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
13.3.1. Major Depressive Disorder
13.3.2. Schizophrenia and Bipolar I Disorder
13.3.3. Obsessive-Compulsive Disorders (OCD)
13.3.4. Anxiety Disorder
13.3.5. Others
13.4. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
13.5.1. Germany
13.5.2. U.K.
13.5.3. France
13.5.4. Spain
13.5.5. Italy
13.5.6. Rest of Europe
13.6. Europe Depression Drugs Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Disease Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Germany Depression Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
14.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
14.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
14.2.3. Atypical Antidepressants
14.2.4. Tricyclic Antidepressants
14.2.5. Others
14.3. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
14.3.1. Major Depressive Disorder
14.3.2. Schizophrenia and Bipolar I Disorder
14.3.3. Obsessive-Compulsive Disorders (OCD)
14.3.4. Anxiety Disorder
14.3.5. Others
14.4. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Germany Depression Drugs Market Attractiveness Analysis
14.5.1. By Drug Class
14.5.2. By Disease Type
14.5.3. By Distribution Channel
15. France Depression Drugs Market Analysis and Forecast
15.1. Introduction
15.2. France Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
15.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
15.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
15.2.3. Atypical Antidepressants
15.2.4. Tricyclic Antidepressants
15.2.5. Others
15.3. France Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
15.3.1. Major Depressive Disorder
15.3.2. Schizophrenia and Bipolar I Disorder
15.3.3. Obsessive-Compulsive Disorders (OCD)
15.3.4. Anxiety Disorder
15.3.5. Others
15.4. France Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
15.4.1. Hospital Pharmacies
15.4.2. Retail Pharmacies
15.4.3. Online Pharmacies
15.5. France Depression Drugs Market Attractiveness Analysis
15.5.1. By Drug Class
15.5.2. By Disease Type
15.5.3. By Distribution Channel
16. U.K. Depression Drugs Market Analysis and Forecast
16.1. Introduction
16.2. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
16.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
16.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
16.2.3. Atypical Antidepressants
16.2.4. Tricyclic Antidepressants
16.2.5. Others
16.3. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
16.3.1. Major Depressive Disorder
16.3.2. Schizophrenia and Bipolar I Disorder
16.3.3. Obsessive-Compulsive Disorders (OCD)
16.3.4. Anxiety Disorder
16.3.5. Others
16.4. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
16.4.1. Hospital Pharmacies
16.4.2. Retail Pharmacies
16.4.3. Online Pharmacies
16.5. U.K. Depression Drugs Market Attractiveness Analysis
16.5.1. By Drug Class
16.5.2. By Disease Type
16.5.3. By Distribution Channel
17. Italy Depression Drugs Market Analysis and Forecast
17.1. Introduction
17.2. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
17.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
17.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
17.2.3. Atypical Antidepressants
17.2.4. Tricyclic Antidepressants
17.2.5. Others
17.3. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
17.3.1. Major Depressive Disorder
17.3.2. Schizophrenia and Bipolar I Disorder
17.3.3. Obsessive-Compulsive Disorders (OCD)
17.3.4. Anxiety Disorder
17.3.5. Others
17.4. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
17.4.1. Hospital Pharmacies
17.4.2. Retail Pharmacies
17.4.3. Online Pharmacies
17.5. Italy Depression Drugs Market Attractiveness Analysis
17.5.1. By Drug Class
17.5.2. By Disease Type
17.5.3. By Distribution Channel
18. Spain Depression Drugs Market Analysis and Forecast
18.1. Introduction
18.2. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
18.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
18.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
18.2.3. Atypical Antidepressants
18.2.4. Tricyclic Antidepressants
18.2.5. Others
18.3. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
18.3.1. Major Depressive Disorder
18.3.2. Schizophrenia and Bipolar I Disorder
18.3.3. Obsessive-Compulsive Disorders (OCD)
18.3.4. Anxiety Disorder
18.3.5. Others
18.4. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
18.4.1. Hospital Pharmacies
18.4.2. Retail Pharmacies
18.4.3. Online Pharmacies
18.5. Spain Depression Drugs Market Attractiveness Analysis
18.5.1. By Drug Class
18.5.2. By Disease Type
18.5.3. By Distribution Channel
19. Asia Pacific Depression Drugs Market Analysis and Forecast
19.1. Introduction
19.2. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
19.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
19.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
19.2.3. Atypical Antidepressants
19.2.4. Tricyclic Antidepressants
19.2.5. Others
19.3. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
19.3.1. Major Depressive Disorder
19.3.2. Schizophrenia and Bipolar I Disorder
19.3.3. Obsessive-Compulsive Disorders (OCD)
19.3.4. Anxiety Disorder
19.3.5. Others
19.4. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
19.4.1. Hospital Pharmacies
19.4.2. Retail Pharmacies
19.4.3. Online Pharmacies
19.5. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
19.5.1. China
19.5.2. Japan
19.5.3. India
19.5.4. Australia & New Zealand
19.5.5. Rest of Asia Pacific
19.6. Asia Pacific Depression Drugs Market Attractiveness Analysis
19.6.1. By Drug Class
19.6.2. By Disease Type
19.6.3. By Distribution Channel
19.6.4. By Country/Sub-region
20. Japan Depression Drugs Market Analysis and Forecast
20.1. Introduction
20.2. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
20.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
20.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
20.2.3. Atypical Antidepressants
20.2.4. Tricyclic Antidepressants
20.2.5. Others
20.3. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
20.3.1. Major Depressive Disorder
20.3.2. Schizophrenia and Bipolar I Disorder
20.3.3. Obsessive-Compulsive Disorders (OCD)
20.3.4. Anxiety Disorder
20.3.5. Others
20.4. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
20.4.1. Hospital Pharmacies
20.4.2. Retail Pharmacies
20.4.3. Online Pharmacies
20.5. Japan Depression Drugs Market Attractiveness Analysis
20.5.1. By Drug Class
20.5.2. By Disease Type
20.5.3. By Distribution Channel
21. China Depression Drugs Market Analysis and Forecast
21.1. Introduction
21.2. China Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
21.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
21.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
21.2.3. Atypical Antidepressants
21.2.4. Tricyclic Antidepressants
21.2.5. Others
21.3. China Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
21.3.1. Major Depressive Disorder
21.3.2. Schizophrenia and Bipolar I Disorder
21.3.3. Obsessive-Compulsive Disorders (OCD)
21.3.4. Anxiety Disorder
21.3.5. Others
21.4. China Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
21.4.1. Hospital Pharmacies
21.4.2. Retail Pharmacies
21.4.3. Online Pharmacies
21.5. China Depression Drugs Market Attractiveness Analysis
21.5.1. By Drug Class
21.5.2. By Disease Type
21.5.3. By Distribution Channel
22. India Depression Drugs Market Analysis and Forecast
22.1. Introduction
22.2. India Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
22.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
22.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
22.2.3. Atypical Antidepressants
22.2.4. Tricyclic Antidepressants
22.2.5. Others
22.3. India Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
22.3.1. Major Depressive Disorder
22.3.2. Schizophrenia and Bipolar I Disorder
22.3.3. Obsessive-Compulsive Disorders (OCD)
22.3.4. Anxiety Disorder
22.3.5. Others
22.4. India Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
22.4.1. Hospital Pharmacies
22.4.2. Retail Pharmacies
22.4.3. Online Pharmacies
22.5. India Depression Drugs Market Attractiveness Analysis
22.5.1. By Drug Class
22.5.2. By Disease Type
22.5.3. By Distribution Channel
23. Australia & New Zealand Depression Drugs Market Analysis and Forecast
23.1. Introduction
23.2. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
23.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
23.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
23.2.3. Atypical Antidepressants
23.2.4. Tricyclic Antidepressants
23.2.5. Others
23.3. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
23.3.1. Major Depressive Disorder
23.3.2. Schizophrenia and Bipolar I Disorder
23.3.3. Obsessive-Compulsive Disorders (OCD)
23.3.4. Anxiety Disorder
23.3.5. Others
23.4. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
23.4.1. Hospital Pharmacies
23.4.2. Retail Pharmacies
23.4.3. Online Pharmacies
23.5. Australia & New Zealand Depression Drugs Market Attractiveness Analysis
23.5.1. By Drug Class
23.5.2. By Disease Type
23.5.3. By Distribution Channel
24. Latin America Depression Drugs Market Analysis and Forecast
24.1. Introduction
24.2. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
24.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
24.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
24.2.3. Atypical Antidepressants
24.2.4. Tricyclic Antidepressants
24.2.5. Others
24.3. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
24.3.1. Major Depressive Disorder
24.3.2. Schizophrenia and Bipolar I Disorder
24.3.3. Obsessive-Compulsive Disorders (OCD)
24.3.4. Anxiety Disorder
24.3.5. Others
24.4. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
24.4.1. Hospital Pharmacies
24.4.2. Retail Pharmacies
24.4.3. Online Pharmacies
24.5. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
24.5.1. Brazil
24.5.2. Mexico
24.5.3. Rest of Latin America
24.6. Latin America Depression Drugs Market Attractiveness Analysis
24.6.1. By Drug Class
24.6.2. By Disease Type
24.6.3. By Distribution Channel
24.6.4. By Country/Sub-region
25. Brazil Depression Drugs Market Analysis and Forecast
25.1. Introduction
25.2. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
25.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
25.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
25.2.3. Atypical Antidepressants
25.2.4. Tricyclic Antidepressants
25.2.5. Others
25.3. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
25.3.1. Major Depressive Disorder
25.3.2. Schizophrenia and Bipolar I Disorder
25.3.3. Obsessive-Compulsive Disorders (OCD)
25.3.4. Anxiety Disorder
25.3.5. Others
25.4. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
25.4.1. Hospital Pharmacies
25.4.2. Retail Pharmacies
25.4.3. Online Pharmacies
25.5. Brazil Depression Drugs Market Attractiveness Analysis
25.5.1. By Drug Class
25.5.2. By Disease Type
25.5.3. By Distribution Channel
26. Mexico Depression Drugs Market Analysis and Forecast
26.1. Introduction
26.2. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
26.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
26.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
26.2.3. Atypical Antidepressants
26.2.4. Tricyclic Antidepressants
26.2.5. Others
26.3. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
26.3.1. Major Depressive Disorder
26.3.2. Schizophrenia and Bipolar I Disorder
26.3.3. Obsessive-Compulsive Disorders (OCD)
26.3.4. Anxiety Disorder
26.3.5. Others
26.4. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
26.4.1. Hospital Pharmacies
26.4.2. Retail Pharmacies
26.4.3. Online Pharmacies
26.5. Mexico Depression Drugs Market Attractiveness Analysis
26.5.1. By Drug Class
26.5.2. By Disease Type
26.5.3. By Distribution Channel
27. Middle East & Africa Depression Drugs Market Analysis and Forecast
27.1. Introduction
27.2. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
27.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
27.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
27.2.3. Atypical Antidepressants
27.2.4. Tricyclic Antidepressants
27.2.5. Others
27.3. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
27.3.1. Major Depressive Disorder
27.3.2. Schizophrenia and Bipolar I Disorder
27.3.3. Obsessive-Compulsive Disorders (OCD)
27.3.4. Anxiety Disorder
27.3.5. Others
27.4. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
27.4.1. Hospital Pharmacies
27.4.2. Retail Pharmacies
27.4.3. Online Pharmacies
27.5. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
27.5.1. GCC Countries
27.5.2. South Africa
27.5.3. Rest of Middle East & Africa
27.6. Middle East & Africa Depression Drugs Market Attractiveness Analysis
27.6.1. By Drug Class
27.6.2. By Disease Type
27.6.3. By Distribution Channel
27.6.4. By Country/Sub-region
28. GCC Countries Depression Drugs Market Analysis and Forecast
28.1. Introduction
28.2. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
28.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
28.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
28.2.3. Atypical Antidepressants
28.2.4. Tricyclic Antidepressants
28.2.5. Others
28.3. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
28.3.1. Major Depressive Disorder
28.3.2. Schizophrenia and Bipolar I Disorder
28.3.3. Obsessive-Compulsive Disorders (OCD)
28.3.4. Anxiety Disorder
28.3.5. Others
28.4. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
28.4.1. Hospital Pharmacies
28.4.2. Retail Pharmacies
28.4.3. Online Pharmacies
28.5. GCC Countries Depression Drugs Market Attractiveness Analysis
28.5.1. By Drug Class
28.5.2. By Disease Type
28.5.3. By Distribution Channel
29. South Africa Depression Drugs Market Analysis and Forecast
29.1. Introduction
29.2. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
29.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
29.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
29.2.3. Atypical Antidepressants
29.2.4. Tricyclic Antidepressants
29.2.5. Others
29.3. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
29.3.1. Major Depressive Disorder
29.3.2. Schizophrenia and Bipolar I Disorder
29.3.3. Obsessive-Compulsive Disorders (OCD)
29.3.4. Anxiety Disorder
29.3.5. Others
29.4. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
29.4.1. Hospital Pharmacies
29.4.2. Retail Pharmacies
29.4.3. Online Pharmacies
29.5. South Africa Depression Drugs Market Attractiveness Analysis
29.5.1. By Drug Class
29.5.2. By Disease Type
29.5.3. By Distribution Channel
30. Competition Landscape
30.1. Competition Matrix
30.2. Market Share Analysis, by Company, 2019
30.3. Company Profiles
30.3.1. Novartis AG
30.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.1.2. Company Financials
30.3.1.3. Growth Strategies
30.3.1.4. SWOT Analysis
30.3.2. GlaxoSmithKline plc
30.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.2.2. Company Financials
30.3.2.3. Growth Strategies
30.3.2.4. SWOT Analysis
30.3.3. Eli Lilly and Company
30.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.3.2. Company Financials
30.3.3.3. Growth Strategies
30.3.3.4. SWOT Analysis
30.3.4. Pfizer, Inc.
30.3.4.1. Company Overview (HQ, Business Segments)
30.3.4.2. Company Financials
30.3.4.3. Growth Strategies
30.3.4.4. SWOT Analysis
30.3.5. Allergan plc
30.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.5.2. Company Financials
30.3.5.3. Growth Strategies
30.3.5.4. SWOT Analysis
30.3.6. Takeda Pharmaceutical Company Limited
30.3.6.1. Company Overview (HQ, Business Segments)
30.3.6.2. Company Financials
30.3.6.3. Growth Strategies
30.3.6.4. SWOT Analysis
30.3.7. AstraZeneca plc
30.3.7.1. Company Overview (HQ, Business Segments)
30.3.7.2. Company Financials
30.3.7.3. Growth Strategies
30.3.7.4. SWOT Analysis
30.3.8. Johnson & Johnson
30.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.8.2. Company Financials
30.3.8.3. Growth Strategies
30.3.8.4. SWOT Analysis
30.3.9. Abbott
30.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.9.2. Company Financials
30.3.9.3. Growth Strategies
30.3.9.4. SWOT Analysis
30.3.10. Otsuka Pharmaceutical Co., Ltd.
30.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
30.3.10.2. Company Financials
30.3.10.3. Growth Strategies
30.3.10.4. SWOT Analysis
List of Tables
Table 01: Global Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 02: Global Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 03: Global Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 04: Global Depression Drugs Market Value (US$ Mn) Forecast, by Region, 2018-2030
Table 05: North America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 06: North America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 07: North America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 08: North America Depression Drugs Market Value (US$ Mn) Forecast, by Country, 2018-2030
Table 09: U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 10: U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 11: U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 12: Canada Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 13: Canada Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 14: Canada Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 15: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 16: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 17: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 18: Europe Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
Table 19: U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 20: U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 21: U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 22: Spain Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 23: Spain Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 24: Spain Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 25: Germany Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 26: Germany Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 27: Germany Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 28: France Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 29: France Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 30: France Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 31: Italy Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 32: Italy Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 33: Italy Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 34: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 35: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 36: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 37: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
Table 38: Japan Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 39: Japan Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 40: Japan Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 41: China Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 42: China Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 43: China Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 44: India Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 45: India Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 46: India Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 47: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 48: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 49: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 50: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 51: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 52: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 53: Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2018-2030
Table 54: Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 55: Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 56: Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 57: Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 58: Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 59: Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 60: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 61: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 62: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 63: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2018-2030
Table 64: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 65: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 66: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
Table 67: South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018-2030
Table 68: South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
Table 69: South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
List of Figures
Figure 01: Global Depression Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2030
Figure 02: Global Depression Drugs Market Value (US$ Mn) Forecast, 2018-2030
Figure 03: Market Value Share, by Drug Class, 2019
Figure 04: Market Value Share, by Disease Type, 2019
Figure 05: Market Value Share, by Distribution Channel, 2019
Figure 06: Market Value Share, by Region, 2019
Figure 07: Global Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 08: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by SSRIs, 2018-2030
Figure 09: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by SNRIs, 2018-2030
Figure 10: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Atypical Antidepressants, 2018-2030
Figure 11: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Tricyclic Antidepressants, 2018-2030
Figure 12: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030
Figure 13: Global Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 14: Global Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 15: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Major Depressive Disorder, 2018-2030
Figure 16: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Schizophrenia and Bipolar I Disorder, 2018-2030
Figure 17: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Obsessive Compulsive Disorder (OCD), 2018-2030
Figure 18: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Anxiety Disorder, 2018-2030
Figure 19: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030
Figure 20: Global Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 21: Global Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 22: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018-2030
Figure 23: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018-2030
Figure 24: Global Depression Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2018-2030
Figure 25: Global Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 26: Global Depression Drugs Market, by Region, 2019 and 2030
Figure 27: Global Depression Drugs Market Attractiveness Analysis, by Region, 2020-2030
Figure 28: North America Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 29: North America Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 30: North America Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 31: North America Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 32: North America Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 33: North America Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 34: North America Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 35: North America Depression Drugs Market Value Share Analysis, by Country, 2019 and 2030
Figure 36: North America Depression Drugs Market Attractiveness Analysis, by Country, 2020-2030
Figure 37: U.S. Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 38: U.S. Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 39: U.S. Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 40: U.S. Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 41: U.S. Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 42: U.S. Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 43: U.S. Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 44: Canada Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 45: Canada Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 46: Canada Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 47: Canada Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 48: Canada Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 49: Canada Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 50: Canada Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 51: Europe Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 52: Europe Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 53: Europe Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 54: Europe Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 55: Europe Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 56: Europe Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 57: Europe Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 58: Europe Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 59: Europe Depression Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
Figure 60: U.K. Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 61: U.K. Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 62: U.K. Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 63: U.K. Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 64: U.K. Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 65: U.K. Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 66: U.K. Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 67: Spain Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 68: Spain Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 69: Spain Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 70: Spain Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 71: Spain Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 72: Spain Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 73: Spain Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 74: Germany Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 75: Germany Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 76: Germany Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 77: Germany Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 78: Germany Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 79: Germany Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 80: Germany Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 81: France Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 82: France Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 83: France Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 84: France Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 85: France Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 86: France Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 87: France Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 88: Italy Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 89: Italy Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 90: Italy Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 91: Italy Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 92: Italy Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 93: Italy Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 94: Italy Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 95: Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 96: Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 97: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 99: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 100: Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 101: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 102: Asia Pacific Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 103: Asia Pacific Depression Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
Figure 104: Japan Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 105: Japan Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 106: Japan Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 107: Japan Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 108: Japan Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 109: Japan Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 110: Japan Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 111: China Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 112: China Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 113: China Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 114: China Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 115: China Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 116: China Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 117: China Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 118: India Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 119: India Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 120: India Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 121: India Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 122: India Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 123: India Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 124: India Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 125: Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 126: Australia & New Zealand Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 127: Australia & New Zealand Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 128: Australia & New Zealand Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 129: Australia & New Zealand Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 130: Australia & New Zealand Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 131: Australia & New Zealand Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 132: Latin America Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 133: Latin America Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 134: Latin America Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 135: Latin America Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 136: Latin America Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 137: Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 138: Latin America Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 139: Latin America Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 140: Latin America Depression Drugs Market Attractiveness Analysis, by Country /Sub-region, 2020-2030
Figure 141: Brazil Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 142: Brazil Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 143: Brazil Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 144: Brazil Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 145: Brazil Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 146: Brazil Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 147: Brazil Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 148: Mexico Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 149: Mexico Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 150: Mexico Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 151: Mexico Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 152: Mexico Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 153: Mexico Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 154: Mexico Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 155: Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 156: Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 157: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 158: Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 159: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 160: Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 161: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 162: Middle East & Africa Depression Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 163: Middle East & Africa Depression Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
Figure 164: GCC Countries Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 165: GCC Countries Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 166: GCC Countries Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 167: GCC Countries Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 168: GCC Countries Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 169: GCC Countries Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 170: GCC Countries Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Figure 171: South Africa Depression Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
Figure 172: South Africa Depression Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 173: South Africa Depression Drugs Market Attractiveness Analysis, by Drug Class, 2020-2030
Figure 174: South Africa Depression Drugs Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 175: South Africa Depression Drugs Market Attractiveness Analysis, by Disease Type, 2020-2030
Figure 176: South Africa Depression Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 177: South Africa Depression Drugs Market Attractiveness Analysis, by Distribution Channel, 2020-2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Depression Drugs Market Trends, 2020-2030
